Christopher Dakhil

Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial

Edward S. Kim, Vamsidhar Velcheti, Tarek Mekhail et al. · Nature Medicine · 2022 · 161 citations · Full text

Oxybutynin vs Placebo for Hot Flashes in Women With or Without Breast Cancer: A Randomized, Double-Blind Clinical Trial (ACCRU SC-1603)

Roberto A. Leon‐Ferre, Paul J. Novotny, Eric Wolfe et al. · JNCI Cancer Spectrum · 2019 · 88 citations · Full text

Primary efficacy results from B-F1RST, a prospective phase II trial evaluating blood-based tumour mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCLC)

E.S. Kim, Vamsidhar Velcheti, Tarek Mekhail et al. · Annals of Oncology · 2018 · 62 citations · Full text

Medicine, Immunology, Pathology +7

Final efficacy results from B-F1RST, a prospective phase II trial evaluating blood-based tumour mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCLC)

Mark A. Socinski, Vamsidhar Velcheti, Tarek Mekhail et al. · Annals of Oncology · 2019 · 58 citations · Full text

Final Efficacy Results, Medicine, Immunology +7

Prospective clinical evaluation of blood-based tumor mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCLC): Interim B-F1RST results.

Vamsidhar Velcheti, Edward S. Kim, Tarek Mekhail et al. · Journal of Clinical Oncology · 2018 · 42 citations

Immunology, Pathology, Btmb High +17